Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by CalgaryATEon Sep 16, 2020 10:59pm
160 Views
Post# 31572542

RE:RE:The market is bored

RE:RE:The market is bored
#7 Report of preclinical studies for ATB-352 is Q3 2021 (as per the corporate update and also the latest MD&A). As to other catalysts... I'd say the news release for "hiring a US-based senior business development officer to execute the large market partnering." I don't necessarily think it'll spike the SP, but maybe 2-3 months after the hiring the SP might start to gradually start to climb as people start to think a buyout or large market partnering becomes more and more likely. Right now, people are probably pretty confident there won't be a buyout / large partnership anytime soon, because we haven't even hired the guy who'll be doing the negotiating for us yet (and once hired, they'd probably need 2-3 months on the quick end to... ?a year? to negotiate and finalize a buyout / large market partnering).
<< Previous
Bullboard Posts
Next >>